Abbott Sues Boehringer Unit Over Generic Zemplar

Law360, New York (May 31, 2011, 1:43 PM EDT) -- Abbott Laboratories and the Wisconsin Alumni Research Foundation slapped a Boehringer Ingelheim GmbH unit with a patent infringement suit on Thursday in Delaware seeking to block the injectable drug specialist from producing its own version of kidney disease treatment Zemplar.

In the complaint, filed in Delaware federal court, the plaintiffs say Boehringer's Ben Venue Laboratories Inc. has filed an abbreviated new drug application with the U.S. Food and Drug Administration in a bid to sell a generic copy of Zemplar injectable products in violation of three...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.